medigraphic.com
ISSN 1684-1824 (Electronic)

2017, Number 3

<< Back Next >>

Rev Méd Electrón 2017; 39 (3)

Syndrome behavior of patients with prostate benign hyperplasia according to the Traditional Chinese Medicine

Martínez RY, González PEA, Castro MEM, Lovio NY, Ramos MO, Sánchez HVC

Language: Spanish
References: 19
Page: 460-470
PDF size: 97.76 Kb.


ABSTRACT

Introduction: the prostate benign hyperplasia is defined as a histopathologic entity characterized by the prostate gland fibromioadenomatous growth. According to the Traditional Chinese Medicine it is classified in different categories, depending on each patient and his/her main clinical symptoms.
Objective: to establish this disease behavior according to the Traditional Chinese Medicine.
Materials and methods: an observational, descriptive study was carried out in patients diagnosed with prostate benign hyperplasia attended at the Provincial Reference Service of Natural and Traditional Medicine “Dr. Mario E. Dihigo” of Matanzas, in the period from February 2013 to August 2014. The universe was formed by the patients diagnosed with that pathology who assisted to the consultation of Natural and Traditional Medicine. The 100 patients who were ready to participate and voluntarily gave their informed consent were the sample; medical records were written.
Results: Yin deficiency in kidney and liver, and humidity-warm in lower Jiao were the diagnoses that prevailed in the research.
Conclusions: to make the traditional Chinese diagnosis allos to indicate an individualized treatment to the patients while treating the originating cause.


REFERENCES

  1. Carrero-López VM, Cózar-Olmo JM, Miñana-López B. Hiperplasia prostática benigna y síntomas del tracto urinario inferior. Revisión de las evidencias actuales. Actas Urológicas Españolas [Internet]. 2016 [citado 24 Ene 2017];40(5):288-94. Disponible en: https://www.researchgate.net/publication/291952663_Hiperplasia_prostatica_beni gna_y_sintomas_del_tracto_urinario_inferior_Revision_de_las_evidencias_actuales

  2. Dabanović V, Kostić M, Janković S. Cost effectiveness comparison of dutasteride and finasteride in patients with benign prostatic hyperplasia-The Markov model based on data from Montenegro. Vojnosanit Pregl. 2016;73(1). Citado en PubMed; PMID:26964381.

  3. Jaramillo J. Fundamentos de la Medicina Tradicional China. Cap V. Sección 1,2. La Habana: MINSAP; 1988.182-212 p.

  4. Padilla Corral JL. Fisiopatología y Tratamiento en la Medicina Tradicional China. Madrid: Ed. Las Mil y Una Medicinas; 1985.

  5. Álvarez Díaz TA, Tosar Pérez M, Echemendía Sálix C. Medicina Tradicional China. Acupuntura, moxibustión y medicina herbolaria. La Habana: Editorial UH; 2014. 174-75 p.

  6. Dirección de Registros Médicos y Estadísticas de Salud. Anuario Estadístico de Salud 2013 [Internet]. La Habana: MINSAP; 2014 [citado 15 Ene 2016]. Disponible en: http://www.sld.cu/galerias/pdf/sitios/dne/anuario_estadistico_de_salud_2013_e.pd f

  7. Hospital Docente Clínico Quirúrgico Faustino Pérez. Anuario estadístico. Matanzas: Hospital Docente Clínico Quirúrgico Faustino Pérez; 2013.

  8. Pejčić T, Aćimović M, Džamić Z, et al. Benign prostatic hyperplasia and prostatespecific antigen. VojnosanitetskiPregled. 2015;72(5):447-53. Citado en PubMed; PMID:26165054.

  9. Wang J, Xiao Y, Wang Z-g, et al. Combination therapy of Xipayimaizipizi Capsules and Tamsulosin for benign prostatic hyperplasia. Zhonghua NanKe Xue. 2015;21(11):1005-9. Citado en PubMed; PMID: 26738328.

  10. Wang M, Guo L, Duan F, et al. Prostatic arterial embolization for the treatment of lower urinary tract symptoms as a result of large benign prostatic hyperplasia: A prospective single-center investigation. Int J Urol. 2015;22(8):766-72. Citado en PubMed; PMID: 25950927.

  11. Weibl P, Klatte T, Laurinc P, et al. Patient's behavior and attitudes toward the management of benign prostatic hyperplasia among patients with the risk of disease progression: prospective study by "Prostate and Expectations of Treatment Epidemiology Research (PETER) study group". Wien KlinWochenschrift. 2015;127(9-10):363-8. Citado en PubMed; PMID: 25447967.

  12. Udeh EI, Ofoha CG, Adewole DA, et al. A cost effective analysis of fixed-dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy for benign prostatic hyperplasia in Nigeria: a middle income perspective; using an interactive Markov model. BMC Cancer. 2016;16:1-9. Citado en PubMed; PMID: 27388750.

  13. Carnevalo FC. También la próstata. Tratamiento mediante embolización de la hipertrofia benigna de próstata. Intervencionismo [Internet]. 2016 [citado 24 Ene 2017]; 16(2): 13-6. Disponible en: http://revistaintervencionismo.com/wpcontent/ uploads/2016/02/2016_02_Editorial.pdf

  14. Latil A, Pétrissans MT, Rouquet J, et al. Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015 Dec;75(16):1857-67. Citado en PubMed; PMID: 26306400.

  15. Ju X-b, Gu X-j, Zhang Z-Y, et al. [Efficacy and safety of Saw Palmetto Extract Capsules in the treatment of benign prostatic hyperplasia]. Zhonghua Nan Ke Xue . 2015;21(12):1098-101. Citado en PubMed; PMID: 26817302.

  16. Dobrek Ł, Thor PJ. Benign prostatic hyperplasia - progress in pathophysiology and management. Pol Merkur Lekarski. 2015;39(233):263-70. Citado en PubMed; PMID: 26637089.

  17. Nogueira Pérez CA. Acupuntura II. Fisiología, patología, semiología y terapéutica en Medicina Tradicional China. Valladolid: Ediciones CEMETC SL; 1998.

  18. Flaws B, Sionneau P. The treatment of modern Western diseases with Chinese medicine: a textbook & clinical manual. 2da ed [Internet]. Colorado: Blue Poppy Enterprises; 2005 [citado 25 Jul 2015]. 87-95 p. Disponible en: http://www.biblio.nhat-nam.ru/The_Treatment_of_Modern_Western_Diseases.pdf

  19. Zheng JX, Xiao YC, Hu YR, et al. Exendin-4 shows no effects on the prostatic index in high-fat-diet-fed rat with benign prostatic hyperplasia by improving insulin resistance. Andrologia. 2015;47(2):236-42. Citado en Pub Med; PMID: 24605934.




2020     |     www.medigraphic.com